(UroToday.com) The 2023 GU ASCO annual meeting included an oral abstract session on renal cell carcinoma (RCC), featuring a presentation by Dr. Brian Shuch discussing results from ZIRCON, a phase 3 ...

Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase ...

Alicia Morgans interviews Samuel Denmeade about the TRANSFORMER trial and Bipolar Androgen Therapy (BAT) for prostate cancer. Dr. Denmeade explains that the trial, involving 200 patients, compared ...

We aim to determine the prognostic significance of glutathione S-transferase Pi 1 DNA methylation (mGSTP1) in two independent prostate cancer cohorts with long-term clinical follow-up data. We first ...

Compelling evidence has solidified the notion of early treatment intensification in managing patients with metastatic hormone-sensitive prostate cancer (mHSPC). Landmark trials have provided Level 1 ...

Testicular germ cell tumors are the most common solid malignancies in young men, with increasing incidence worldwide. Broadly classified into seminomas and non-seminomas, they exhibit distinct ...

There is no organized prostate cancer screening in Germany. The aim of this study was to investigate the development of incidence and survival in patients with primary malignant tumors of the prostate ...

Immune Checkpoints Inhibitors (ICI) have changed the therapeutic landscape of metastatic renal cell carcinoma first-line treatment with complete response (CR) at metastatic sites observed in 10 to 15% ...

Hashim Hashim joins Diane Newman for a conversation on the definitions of lower urinary tract dysfunction and the role and timing of urodynamics in the diagnosis of the specific condition. They also ...

At the World Congress of Endourology and Uro-Technology, Bruce Gao presents a case study comparing holmium laser enucleation of the prostate (HoLEP) and thulium fiber laser enucleation of the prostate ...

Adverse pathology (AP) is often used as an intermediate end point for long-term outcomes in men with prostate cancer (PCa) who are active surveillance candidates. The association between a commonly ...

Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024. Dr. Sartor discusses the ARANOTE, PEACE-3, and the SPLASH trials. The ARANOTE, PEACE-3, ...